These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 15367333)

  • 1. The role of circulating anti-p53 antibodies in patients with advanced non-small cell lung cancer and their correlation to clinical parameters and survival.
    Bergqvist M; Brattström D; Larsson A; Hesselius P; Brodin O; Wagenius G
    BMC Cancer; 2004 Sep; 4():66. PubMed ID: 15367333
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The presence of anti-p53 antibodies in sera from patients with oesophageal carcinoma: correlation to treatment, tumour volume and survival.
    Bergström S; Dreilich M; Wagenius G; Brattström D; Larsson A; Hesselius P; Bergqvist M
    In Vivo; 2004; 18(5):615-20. PubMed ID: 15523902
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Presence of serum anti-p53 antibodies is associated with pleural effusion and poor prognosis in lung cancer patients.
    Lai CL; Tsai CM; Tsai TT; Kuo BI; Chang KT; Fu HT; Perng RP; Chen JY
    Clin Cancer Res; 1998 Dec; 4(12):3025-30. PubMed ID: 9865916
    [TBL] [Abstract][Full Text] [Related]  

  • 4. P53 auto-antibodies in non-small cell lung cancer patients can predict increased life expectancy after radiotherapy.
    Bergqvist M; Brattström D; Larsson A; Holmertz J; Hesselius P; Rosenberg L; Wagenius G; Brodin O
    Anticancer Res; 1998; 18(3B):1999-2002. PubMed ID: 9677456
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of antibodies against p53 in lung cancer patients appears to be dependent on the type of p53 mutation.
    Winter SF; Minna JD; Johnson BE; Takahashi T; Gazdar AF; Carbone DP
    Cancer Res; 1992 Aug; 52(15):4168-74. PubMed ID: 1322237
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic significance of serum p53 antibodies in squamous cell carcinoma of the lung.
    Komiya T; Hirashima T; Takada M; Masuda N; Yasumitsu T; Nakagawa K; Hosono Y; Kikui M; Tsuji S; Fukuoka M; Kawase I
    Anticancer Res; 1997; 17(5B):3721-4. PubMed ID: 9427768
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Correlation analysis among expression of ERCC-1, metallothionein, p53 and platinum resistance and prognosis in advanced non-small cell lung cancer].
    Huang PY; Liang XM; Lin SX; Luo RZ; Hou JH; Zhang L
    Ai Zheng; 2004 Jul; 23(7):845-50. PubMed ID: 15248926
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor expression of S100A6 correlates with survival of patients with stage I non-small-cell lung cancer.
    De Petris L; Orre LM; Kanter L; Pernemalm M; Koyi H; Lewensohn R; Lehtiö J
    Lung Cancer; 2009 Mar; 63(3):410-7. PubMed ID: 18620780
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vascular endothelial growth factor, p53, Rb, Bcl-2 expression and response to chemotherapy in advanced non-small cell lung cancer.
    Ludovini V; Gregorc V; Pistola L; Mihaylova Z; Floriani I; Darwish S; Stracci F; Tofanetti FR; Ferraldeschi M; Di Carlo L; Ragusa M; Daddi G; Tonato M
    Lung Cancer; 2004 Oct; 46(1):77-85. PubMed ID: 15364135
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum p53 autoantibodies as prognostic marker in patients with oesophageal carcinoma.
    Bergqvist AS; Bergqvist M; Brattstrom D; Hesselius P; Larsson A; Brodin O; Wagenius G
    Anticancer Res; 2001; 21(6A):4141-5. PubMed ID: 11911308
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The utility of p53 immunostaining of transbronchial biopsy specimens of lung cancer: p53 overexpression predicts poor prognosis and chemoresistance in advanced non-small cell lung cancer.
    Kawasaki M; Nakanishi Y; Kuwano K; Yatsunami J; Takayama K; Hara N
    Clin Cancer Res; 1997 Jul; 3(7):1195-200. PubMed ID: 9815799
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An association between preoperative anemia and decreased survival in early-stage non-small-cell lung cancer patients treated with surgery alone.
    Yovino S; Kwok Y; Krasna M; Bangalore M; Suntharalingam M
    Int J Radiat Oncol Biol Phys; 2005 Aug; 62(5):1438-43. PubMed ID: 16029805
    [TBL] [Abstract][Full Text] [Related]  

  • 13. p53 and P-glycoprotein expression do not correlate with survival in nonsmall cell lung cancer: a long-term study and literature review.
    Haque AK; Adegboyega P; Al-Salameh A; Vrazel DP; Zwischenberger J
    Mod Pathol; 1999 Dec; 12(12):1158-66. PubMed ID: 10619270
    [TBL] [Abstract][Full Text] [Related]  

  • 14. p53 gene mutations are associated with shortened survival in patients with advanced non-small cell lung cancer: an analysis of medically managed patients.
    Murakami I; Hiyama K; Ishioka S; Yamakido M; Kasagi F; Yokosaki Y
    Clin Cancer Res; 2000 Feb; 6(2):526-30. PubMed ID: 10690534
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The detection of quantitative serum p53 protein in lung cancer.
    Sen E; Gönüllü U; Akar N
    Tuberk Toraks; 2005; 53(3):231-7. PubMed ID: 16258881
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum vascular endothelial growth factor (VEGF) and bcl-2 levels in advanced stage non-small cell lung cancer.
    Tas F; Duranyildiz D; Oguz H; Camlica H; Yasasever V; Topuz E
    Cancer Invest; 2006 Oct; 24(6):576-80. PubMed ID: 16982461
    [TBL] [Abstract][Full Text] [Related]  

  • 17. p53 protein in non-small cell lung cancer as quantitated by enzyme-linked immunosorbent assay: relation to prognosis.
    Pappot H; Francis D; Brünner N; Grondahl-Hansen J; Osterlind K
    Clin Cancer Res; 1996 Jan; 2(1):155-60. PubMed ID: 9816102
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum p53 antibodies: predictors of survival in small-cell lung cancer?
    Murray PV; Soussi T; O'Brien ME; Smith IE; Brossault S; Norton A; Ashley S; Tavassoli M
    Br J Cancer; 2000 Dec; 83(11):1418-24. PubMed ID: 11076647
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Circulating antibodies against p53 protein in patients with ovarian carcinoma. Correlation with clinicopathologic features and survival.
    Angelopoulou K; Rosen B; Stratis M; Yu H; Solomou M; Diamandis EP
    Cancer; 1996 Nov; 78(10):2146-52. PubMed ID: 8918407
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II randomized controlled trial of an epidermal growth factor vaccine in advanced non-small-cell lung cancer.
    Neninger Vinageras E; de la Torre A; Osorio Rodríguez M; Catalá Ferrer M; Bravo I; Mendoza del Pino M; Abreu Abreu D; Acosta Brooks S; Rives R; del Castillo Carrillo C; González Dueñas M; Viada C; García Verdecia B; Crombet Ramos T; González Marinello G; Lage Dávila A
    J Clin Oncol; 2008 Mar; 26(9):1452-8. PubMed ID: 18349395
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.